Background: In the field of tuberculosis and non-tuberculous mycobacterial (NTM) disease we are looking back on an exciting year 2024 with more than 10,000 publications listed in PubMed.
Methods: Our aim, to review the scientific literature of the year 2024, is challenged by the enormous number of publications. Therefore, if your article is not included or your favorite field of mycobacteriology not covered, please forgive us. Our "Year in Review" is very much clinically oriented with lesser emphasis on basic science, microbiology, and biotechnology.
Results: Members of the steering committee of the Tuberculosis Network European Trials group (TBnet; www.tbnet.eu) report on 139 publications in the fields of epidemiology, prevention, diagnosis, and treatment of tuberculosis and NTM diseases published in 2024 that we found particularly important. We report publications separately for tuberculosis in children and adults and for NTM disease and provide a brief overview of newer technologies in the diagnostic pipeline. Furthermore, we summarize priorities for tuberculosis and NTM disease research, development, and implementation, all of which represent the perspective of our combined clinical experience.
Conclusions: This Year in Review provides a concise summary of the clinically relevant highlights of the published literature in tuberculosis and NTM diseases in 2024.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888605 | PMC |
| http://dx.doi.org/10.20411/pai.v10i2.791 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis.
Ther Adv Respir Dis
March 2025
Department of Medicine, National Jewish Health, Denver, CO, USA.
Nontuberculous mycobacteria (NTM) are ubiquitous, opportunistic pathogens that can cause lung disease in people with non-cystic fibrosis bronchiectasis (NCFB) and cystic fibrosis (CF). The incidence of NTM pulmonary infections and lung disease has continued to increase worldwide over the last decade among both groups. Notably, women with NCFB NTM pulmonary disease (NTM-PD) bear a disproportionate burden with NTM rates increasing in this population as well as having consistently higher incidence of NTM-PD compared to men.
View Article and Find Full Text PDFProspective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis.
PLoS One
March 2025
Department of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Background: Routine screening for nontuberculous mycobacterial (NTM) lung disease is dependent on sputum cultures. This is particularly challenging in the cystic fibrosis (CF) population due to reduced sputum production and low culture sensitivity. Biomarkers of infection that do not rely on sputum may lead to earlier diagnosis, but validation trials require a unique prospective design.
View Article and Find Full Text PDFA Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.
Pathog Immun
March 2025
MRC Clinical Trials Unit, University College London, London, United Kingdom.
Background: In the field of tuberculosis and non-tuberculous mycobacterial (NTM) disease we are looking back on an exciting year 2024 with more than 10,000 publications listed in PubMed.
Methods: Our aim, to review the scientific literature of the year 2024, is challenged by the enormous number of publications. Therefore, if your article is not included or your favorite field of mycobacteriology not covered, please forgive us.
An immunocompetent rat model of Mycobacterium abscessus multinodular granulomatous lung infection.
Tuberculosis (Edinb)
March 2025
Basil Hetzel Institute for Translational Health Research, Woodville, South Australia, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia. Electronic address:
Animal models that can mimic progressive granulomatous pulmonary disease (PD) due to non-tuberculous mycobacteria (NTM) have not been established in rats to date. These models could assist with the study of the pathophysiology of NTM-PD as well as the preclinical development of new therapies. In the present study, an immunocompetent rat model of progressive Mycobacterium abscessus (MABs)- PD was developed using MABs originating from a patient with cystic fibrosis.
View Article and Find Full Text PDFEpigenome-wide analysis reveals potential biomarkers for radiation-induced toxicity risk in prostate cancer.
Clin Epigenetics
March 2025
Genetics in Cancer and Rare Diseases Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.
Background: Prostate cancer is the second most common cancer globally, with radiation therapy (RT) being a key treatment for clinically localized and locally advanced cases. Given high survival rates, addressing long-term side effects of RT is crucial for preserving quality-of-life. Radiogenomics, the study of genetic variations affecting response to radiation, has primarily focussed on genomic biomarkers, while DNA methylation studies offer insights into RT responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!